Comments on: Teva Decides Not to Wait for U.S. Biosimilars Legislation http://crossborderbiotech.ca/2009/02/19/teva-decides-not-to-wait-for-biosimilars-legislation/ Biotechnology, Health and Business in Canada, the United States and Worldwide Mon, 02 Apr 2012 12:31:04 +0000 hourly 1 http://wordpress.com/ By: Biotech Trends Update: Teva’s BLA for Neupoval is Accepted at the FDA « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/19/teva-decides-not-to-wait-for-biosimilars-legislation/comment-page-1/#comment-1335 Wed, 03 Feb 2010 02:33:38 +0000 http://crossborderbiotech.ca/?p=654#comment-1335 [...] 2, 2010 · Leave a Comment Teva’s decision last year to submit a full biologic license application (BLA) for Neupoval looks positively prescient today.  Teva’s product is already sold in the EU as a [...]

]]> By: Top 10 Cross-Border Biotech Blog Posts of 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/19/teva-decides-not-to-wait-for-biosimilars-legislation/comment-page-1/#comment-1220 Sun, 03 Jan 2010 22:21:00 +0000 http://crossborderbiotech.ca/?p=654#comment-1220 [...] Teva Decides Not to Wait for U.S. Biosimilars Legislation [...]

]]> By: Wednesday Brain Dump: March 11, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/19/teva-decides-not-to-wait-for-biosimilars-legislation/comment-page-1/#comment-132 Wed, 11 Mar 2009 22:27:59 +0000 http://crossborderbiotech.ca/?p=654#comment-132 [...] Waiting for Regulation: Like Teva’s decision in February, Momenta Pharmaceuticals doesn’t think it needs to wait for a follow-on biologics [...]

]]>